HCWB — Hcw Biologics Balance Sheet
0.000.00%
- $2.81m
- $8.52m
- $2.57m
Annual balance sheet for Hcw Biologics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 8.46 | 36.7 | 32.1 | 3.6 | 4.67 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 2.5 | 0.133 | 0.418 | 1.54 | 0.582 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 12.1 | 40.5 | 34.1 | 6.4 | 5.7 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.62 | 1.12 | 10.8 | 20.5 | 22.9 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 15.4 | 53.5 | 46.8 | 28.5 | 30.2 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 1 | 2.32 | 2.96 | 8.75 | 29.6 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1 | 2.32 | 9.38 | 15.1 | 37 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 14.4 | 51.2 | 37.4 | 13.5 | -6.77 |
| Total Liabilities & Shareholders' Equity | 15.4 | 53.5 | 46.8 | 28.5 | 30.2 |
| Total Common Shares Outstanding |